 Protagonist Therapeutics Inc NASDAQ: PTGX has selected PN-235 JNJ-77242113 as the final candidate for all clinical studies in multiple indications based on the intervention of the Interleukin-23 IL-23 pathway, under its collaboration with Janssen Biotech Inc, a unit of Johnson Johnson NYSE: JNJ. In addition to the previously announced Phase 2 study of PN-235 in psoriasis, new Phase 2 studies of PN-235 in inflammatory bowel diseases IBD will commence in late 2022. 